3 results
Approved WMOCompleted
To determine the pharmacokinetic properties of a new elacridar formulation
Approved WMOCompleted
The primary objective of this study is to obtain clinical proof of principle that the addition of a PgP/BCRP inhibitor increases CNS concentrations of tyrosine kinase inhibitors by inhibition of drug efflux transporter function in the blood brain…
Approved WMORecruiting
We aim to optimize the treatment of rheumatoid arthritis patients using concentration measurements. By doing this we hope to reduce the overexposure to the drug, save costs and reduce the number of adverse events, especially infections. The goal of…